Eli Lilly: The Buzz Is Not Over

Summary:

  • Eli Lilly’s weight-loss drug Zepbound, with increasing demand and expected insurance coverage, indicates a significant growth opportunity.
  • Continued success in GLP-1 therapies positions LLY as a leader in the obesity management market, poised for profitability.
  • Despite potential risks, the Company’s robust pipeline and market momentum suggest a strong buy as the obesity drug sector expands.

Indianapolis - April 2016: Eli Lilly and Company V

jetcityimage

Investment Thesis

I believe Eli Lilly (NYSE:LLY) is poised for continual growth due to the significant demand for weight-loss drugs and the increasing insurance coverage. My perspective is a belief in the future of GLP-1 therapies, particularly those targeting obesity. My

Price / Earnings (FWD)

Price / Sales (FWD)

Price / Cash Flow (FWD)

Novo Nordisk

101.75

16.75

92.03

Sector Median

29.27

4.13

16.32

Percent Difference

247.64%

305.81%

463.94%


Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Thomas Potter is an independent investor as this publication has been produced for informational purposes only. This is not investment advice. Please do your own due diligence and invest at your own risk.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Leave a Reply

Your email address will not be published. Required fields are marked *